---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-23-000093"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2023-08-23T23:59:59+00:00"
generated_at: "2026-06-11T05:16:21.893742+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exelixis CMO Vicki Goodman departs effective August 23, 2023; entitled to severance benefits

## Summary
- Vicki L. Goodman, EVP Product Development & Medical Affairs and CMO, concludes service effective August 23, 2023.
- Goodman is eligible for payments under Exelixis' Change in Control and Severance Benefit Plan.
- No successor or interim CMO has been named in this filing.

## SEC filing metadata
- accession: 0000939767-23-000093
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2023-08-23T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976723000093/0000939767-23-000093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976723000093/exel-20230823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-23-000093
- JSON: https://secwatch.observer/filing/0000939767-23-000093.json
- Plain text: https://secwatch.observer/filing/0000939767-23-000093.txt

## Key facts
- Executive change
  Vicki L. Goodman departed as Chief Medical Officer at EXELIXIS, INC..
  - Action: departed
  - Role: Chief Medical Officer
  source text: Effective August 23, 2023, Vicki L. Goodman, M.D., will conclude her service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer of Exelixis, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/939767/000093976723000093/0000939767-23-000093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.